Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VSTM

DatePrice TargetRatingAnalyst
3/24/2025$7.00 → $10.00Buy
H.C. Wainwright
12/31/2024$13.00 → $20.00Buy
BTIG Research
9/30/2024$13.00Buy
Guggenheim
11/21/2023$27.00Buy
BTIG Research
9/27/2023$21.00Buy
B. Riley Securities
6/15/2023$24.00 → $36.00Neutral → Buy
Mizuho
9/7/2022$6.00Buy
Alliance Global Partners
4/29/2022$6.00 → $5.00Overweight
Cantor Fitzgerald
More analyst ratings

$VSTM
Press Releases

Fastest customizable press release news feed in the world

See more
  • Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

    VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor regressions in preclinical KRAS G12D models, including complete responses in a colorectal cancer model In a patient-derived LGSOC xenograft model, an FAK inhibitor addition to avutometinib augmented tumor regression with stronger inhibition of MAPK, PI3K and YAP/TEAD signaling than either agent alone The combination of avutometinib, a RAF/MEK clamp, with a pan-RAF inhibitor led to strong tumor regressions in multiple NRAS- and BRAF-driven tumor models corresponding with nearly complete shutd

    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market

    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual cases by 2030 and a staggering 75% increase by 2050. According to the World Health Organization (WHO), breast cancer cases are projected to rise by nearly 40% by 2050. Despite the concerning trends in cancer incidence, 2025 has seen key advancements from biotech companies at the forefront of oncology research, with Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Cardiff Oncology, Inc. (NASDAQ:CRDF

    $ALXO
    $CRDF
    $EXEL
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$VSTM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VSTM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$VSTM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VSTM
SEC Filings

See more

$VSTM
Leadership Updates

Live Leadership Updates

See more
  • Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market

    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

    New executive leadership supports the company's transition to a fully integrated commercial-stage organization in a year of transformative growth with a potential new product launch in mid-2025. Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. "We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and th

    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

    Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

    $APLT
    $RVPH
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VSTM
Financials

Live finance-specific insights

See more

$VSTM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more